Drug Trial News

RSS

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.

30 Jan 2014

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.

30 Jan 2014

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new pre-clinical data demonstrating the inhibitory effects of GFT505 on the proliferation of cancer cells of different origins.

30 Jan 2014

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Omeros Corporation today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.

29 Jan 2014

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it will announce the results of its Phase 2a clinical trial for the company's ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes on January 30, 2014.

28 Jan 2014

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Cell Therapeutics, Inc.today announced that the Gynecologic Oncology Group informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex as maintenance therapy in ovarian cancer.

28 Jan 2014

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Pfizer Inc. today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer.

28 Jan 2014

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

Scientists have begun the first human clinical trial of EDP-788, an investigational oral antibiotic intended to treat methicillin-resistant Staphylococcus aureus (MRSA) infections.

27 Jan 2014

Myelin Repair Foundation enters into agreement with NIH to assess MRF-008 for multiple sclerosis

The Myelin Repair Foundation today announced it has entered a Cooperative Research and Development Agreement with the National Institutes of Health to assess MRF-008, as a potential therapeutic for multiple sclerosis. This CRADA will facilitate collaboration between the MRF and National Institute of Neurological Disorders and Stroke at the NIH Clinical Center to study MRF-008, a drug identified by the MRF as a potential neuroprotective therapeutic to enhance repair in multiple sclerosis patients.

27 Jan 2014

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013.

27 Jan 2014

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

27 Jan 2014

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

Novocure announced today that the first patient has enrolled in the EF-20 Study, an open label, pilot clinical trial of NovoTTF Therapy plus gemcitabine as first-line therapy for patients with locally advanced and metastatic pancreatic adenocarcinoma.

25 Jan 2014

TherapeuticsMD starts TX 12-002-HR phase 3 clinical trial for secondary amenorrhea

TherapeuticsMD, Inc., a women's healthcare company, announced today that it has initiated the SPRY Trial, a randomized, placebo-controlled phase 3 clinical trial designed to evaluate the safety and efficacy of TX 12-002-HR, its oral progesterone candidate for secondary amenorrhea, a condition treated to maintain fertility in young premenopausal women.

24 Jan 2014

e-Therapeutics temporarily stops phase I trials of ETS2101 due to drug supply issue

e-Therapeutics plc today announces that recruitment of patients into both of the ongoing phase I trials of ETS2101 has been halted temporarily because of a practical issue with stored drug for the trials.

24 Jan 2014

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Pfizer Inc. (NYSE: PFE) announced today top-line results from a Phase 3 study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain.

24 Jan 2014

Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces positive top-line results from its Phase 2 clinical study with PSX1002 in patients with moderate to severe chronic obstructive pulmonary disease.

23 Jan 2014

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi's sarcoma.

23 Jan 2014

EORTC trial follow-up shows chemo-radiotherapy for patients with rectal cancer does not improve survival

Appearing in Lancet Oncology, long term results of EORTC trial 22921 with 10.4 years median follow-up show that 5-FU (fluorouracil) based adjuvant chemotherapy after preoperative (chemo)-radiotherapy for patients with cT3-resectable T4 M0 rectal cancer does not improve survival or disease-free survival.

23 Jan 2014

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Starpharma today announced that it has received the necessary approvals to commence a phase 1 human clinical trial for its dendrimer-enhanced docetaxel (Taxotere®) chemotherapeutic product, referred to as DEP™-Docetaxel.

23 Jan 2014

New scientific article shows that Patrys' PAT-SC1 safe, well-tolerated in gastric cancer patients

Patrys Limited, a clinical stage biotechnology company is pleased to announce the publication of a new scientific article regarding its product PAT-SC1 in the Oncology Reports journal. The article is currently available online and will be included in a future print edition of the journal.

22 Jan 2014

Drug Trial News

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

Myelin Repair Foundation enters into agreement with NIH to assess MRF-008 for multiple sclerosis

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

TherapeuticsMD starts TX 12-002-HR phase 3 clinical trial for secondary amenorrhea

e-Therapeutics temporarily stops phase I trials of ETS2101 due to drug supply issue

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

EORTC trial follow-up shows chemo-radiotherapy for patients with rectal cancer does not improve survival

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

New scientific article shows that Patrys' PAT-SC1 safe, well-tolerated in gastric cancer patients

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Latest News